Intervention Protocol

You have free access to this content

Bortezomib for the treatment of multiple myeloma

  1. Kathleen Scott1,2,*,
  2. Patrick J Hayden3,
  3. Andrew Howman4,
  4. Keith Wheatley4,
  5. Imelda Coyne1

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 11 NOV 2013

DOI: 10.1002/14651858.CD010816


How to Cite

Scott K, Hayden PJ, Howman A, Wheatley K, Coyne I. Bortezomib for the treatment of multiple myeloma (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 11. Art. No.: CD010816. DOI: 10.1002/14651858.CD010816.

Author Information

  1. 1

    Trinity College Dublin, School of Nursing & Midwifery, Dublin, Ireland

  2. 2

    All Ireland Cooperative Oncology Research Group (ICORG), Dublin, Ireland

  3. 3

    St James´s Hospital, Dublin, Ireland

  4. 4

    University of Birmingham, Cancer Research Clinical Trials Unit, School of Cancer Sciences, Birmingham, UK

*Kathleen Scott, scottk2@tcd.ie. Kathleen.Scott@icorg.ie.

Publication History

  1. Publication Status: New
  2. Published Online: 11 NOV 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

We will assess the effects of bortezomib treatment in comparison to other therapies, different doses, treatment administration and schedules of bortezomib, on overall survival (OS), progression-free survival (PFS), response rate (RR), health-related quality of life (HRQoL), adverse events (AE) and treatment-related death.